More than 160 civic leaders, scientists, philanthropists, and educators gathered in Seattle to honor a Nobel Prize achievement, launch the Mary E. Brunkow Fund, and highlight the importance of mentorship, STEM education, and scientific opportunity.
The prize recognizes foundational discoveries about regulatory T cells and the FOXP3 gene that redefined immune tolerance and opened avenues to treat autoimmune disease, enable transplantation, and advance immuno-oncology. ISB celebrates Dr. Brunkow’s leadership and collaborative science.
An international team of researchers, including scientists from the Institute for Systems Biology, has conducted one of the most comprehensive molecular studies of human diversity to date. Published in Cell, the work reveals how ethnicity and geography influence metabolism, immunity, the microbiome, and biological aging — insights that could help advance precision medicine for diverse populations.
ISB’s Dr. Alice Kane explores the biology of aging, highlighting frailty as a key measure of healthspan, new biomarkers of aging, and insights into menopause and women’s health.
ISB researchers use single-cell sequencing to reveal hidden defenses against bacteriophages — and introduce a powerful new way to study phage-microbe interactions.
New research from ISB’s Gibbons Lab shows that computer models of gut metabolism can predict whether probiotics will successfully establish in an individual’s microbiome and how dietary prebiotics shape health-related molecules in the gut. The findings point toward a future of more personalized, predictable microbiome-based interventions.
ISB Professor Dr. Nitin Baliga has been elected to the American Academy of Microbiology as part of the 2026 Fellowship Class — a highly selective honor recognizing exceptional scientific achievement and leadership in the microbial sciences. Baliga joins 62 peers from 14 countries selected through a rigorous peer-review process.
Researchers at the Institute for Systems Biology argue that combining systems biology, longitudinal multiomics data, and artificial intelligence could transform healthcare from reactive treatment to proactive prevention, enabling scientists and clinicians to detect early molecular signs of disease and intervene before symptoms appear.